Investigational drug · Phase 3
Zimislecel
Also called: Formerly known as STx-02, VX-880
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Type 1 Diabetes, Kidney Transplant, Diabetes Mellitus, Type 1.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 1, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
2
Any phase or sponsor naming "Zimislecel"
First trial start
2021
Mar 29, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Zimislecel", any sponsor or status.
Conditions studied
As listed on its trial records.
- Type 1 Diabetes
- Kidney Transplant
- Diabetes Mellitus, Type 1
- Impaired Hypoglycemic Awareness
- Severe Hypoglycemia
Approved drugs for the same conditions: Type 1 diabetes · Cardiovascular and metabolic · Kidney and urology
Largest trials
Live from ClinicalTrials.gov: studies naming "Zimislecel" as an intervention, largest first.
- A Safety, Tolerability, and Efficacy Study of VX-880 and VX-017 in Participants With Type 1 DiabetesPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT04786262 · 57 participants (planned) · Start Mar 29, 2021 · Primary completion Dec 31, 2027
Drug: VX-880; VX-017 · For: Diabetes Mellitus, Type 1; Impaired Hypoglycemic Awareness; Severe Hypoglycemia
Sites: Duarte, California; San Francisco, California; Miami, Florida · 29 sites in all
- An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney TransplantPivotal-lookingRecruiting
Vertex Pharmaceuticals IncorporatedVertex Pharmaceuticals (VRTX)
NCT06832410 · 10 participants (planned) · Start Mar 31, 2025 · Primary completion Sep 17, 2026
Drug: Biological/Vaccine · For: Type 1 Diabetes; Kidney Transplant
Sites: Philadelphia, Pennsylvania; Pittsburgh, Pennsylvania; Madison, Wisconsin · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Translational Barriers to AAV and CRISPR Gene Therapy in Diabetes.
Alharbi AG · Saudi Med J 2026
- Overview of the major clinical trials investigating stem cells-based therapies for diabetes.
Lin TM, Lin TC, Lin CH, et al. · Diabetes Metab 2026
- A UK key opinion leader perspective: Navigating the immunological and logistical transformation brought by stem cell-derived islets for the treatment of type 1 diabetes.
Strakosch T, Forbes S · Diabet Med 2026
- Stem Cell Therapy as a Regenerative Strategy in Hereditary Pancreatitis Postpancreatectomy.
Kuppa P, Chitturi SV, Koundinya S, et al. · Ann Afr Med 2026
- Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes.
Reichman TW, Markmann JF, Odorico J, et al. · N Engl J Med 2025
- Historically Based Perspective on the Immunotherapy of Type 1 Diabetes: Where We Have Been, Where We Are, and Where We May Go.
Cavalli E, Nicoletti GRP, Nicoletti F · J Clin Med 2025
Also in development for Type 1 Diabetes
- THDB0206Phase 32 trials
Tonghua Dongbao Pharmaceutical Co.,Ltd · Type 2 Diabetes, Type 1 Diabetes
- CNP-103Phase 21 trial
COUR Pharmaceutical Development Company, Inc. · Type 1 Diabetes Mellitus, T1D, T1DM
- SAB-142Phase 21 trial
SAb Biotherapeutics, Inc. · Type 1 Diabetes
- VX-264Phase 21 trial
Vertex Pharmaceuticals · Type 1 Diabetes
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Vertex Pharmaceuticals.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.